# Suvorexant 3 - PE-PC

> **NCT07686731** · PHASE4 · NOT_YET_RECRUITING · sponsor: **Northern California Institute of Research and Education** · enrollment: 142 (estimated)

## Conditions studied

- PTSD - Post Traumatic Stress Disorder
- Insomnia
- TBI (Traumatic Brain Injury)

## Interventions

- **DRUG:** Suvorexant
- **DRUG:** Placebo
- **BEHAVIORAL:** Prolonged Exposure Therapy for Primary Care (PE-PC)

## Key facts

- **NCT ID:** NCT07686731
- **Lead sponsor:** Northern California Institute of Research and Education
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-09-01
- **Primary completion:** 2029-03-01
- **Final completion:** 2029-08-30
- **Target enrollment:** 142 (ESTIMATED)
- **Last updated:** 2026-07-07

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07686731

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07686731, "Suvorexant 3 - PE-PC". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07686731. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*